伴TP53突变的典型复杂/单体核型急性髓系白血病的突变谱、临床结局与治疗反应
本研究纳入98例21-60岁复杂/单体核型急性髓系白血病(CK/MK AML)年轻成人,接受标准诱导、巩固及可行时异基因造血干细胞移植。76例二代测序显示TP53突变最常见(49%),与-5/5q-和-17/17p-相关。典型CK/MK AML亚型表现为白细胞计数更低、核型异常数更多、无白血病生存和总生存更差,体外对APR-246敏感但对MDM2拮抗剂MI-77301耐药。
要点
- TP53突变在CK/MK AML中占49%,与-5/5q-及-17/17p-显著相关,与-7/7q-无关。
- 典型CK/MK AML亚型初诊白细胞计数更低、核型异常数更多,无白血病生存和总生存更差。
- 典型CK/MK AML患者样本经依托泊苷诱导后p53信号缺陷,体外对APR-246敏感、对MI-77301耐药。
核心结论
- 伴TP53突变的典型CK/MK AML具有独特临床特征、p53信号缺陷及对p53靶向药物的不同反应,针对TP53突变的新型治疗策略应在临床试验中开发和验证。
研究设计与样本
- 研究纳入98例21-60岁(中位49岁)复杂/单体核型急性髓系白血病年轻成人,接受标准诱导、巩固及可行时同胞或相合无关供者异基因造血干细胞移植。
- 76例患者行54个髓系基因面板二代测序。
主要发现
- 染色体异常最常累及5号染色体(30%)、7号染色体(22%)和17号染色体(21%)。
- TP53突变最常见(49%),与-5/5q-(P < .001)和-17/17p-(P < .001)相关,与-7/7q-无关(P = .370)。
- 典型CK/MK AML亚型初诊白细胞计数显著更低、核型异常数更高,无白血病生存和总生存均更差。
- 典型CK/MK AML患者外周血或骨髓样本经依托泊苷诱导后显示p53信号缺陷。
- 体外药物敏感性分析显示典型CK/MK AML对靶向突变p53的APR-246敏感,但对MDM2拮抗剂MI-77301耐药。
关键数值与推荐
- TP53突变在CK/MK AML中占49%,与-5/5q-(P < .001)和-17/17p-(P < .001)相关,与-7/7q-无关(P = .370)。
- 染色体异常累及5号染色体占30%、7号染色体占22%、17号染色体占21%。
临床怎么用
- 原文结论提出针对CK/MK AML中TP53突变的新型治疗策略应在临床试验中开发和验证。
- 作者未据此给出常规临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The present study aimed to define a subtype of complex/monosomal karyotype (CK/MK) acute myeloid leukemia (AML) by its distinct clinical features, p53 signaling and responses to p53 targeting agents. Ninety-eight young adults (range: 21-60 years; median: 49 years) with CK/MK AML were studied. They received standard induction, consolidation and allogeneic hematopoietic stem cell transplantation from siblings or matched unrelated donors if available. Chromosomal abnormalities most commonly affected chromosome 5 (30%), 7 (22%) and 17 (21%). Next generation sequencing of a 54-myeloid gene panel were available in 76 patients. Tumor protein 53 (TP53) mutations were most common (49%) and associated with the presence of -5/5q- (P < .001) and -17/17p- (P < .001), but not -7/7q- (P = .370). This "typical" CK/MK AML subtype was associated with significantly lower presenting white cell counts, higher number of karyotypic abnormalities, and inferior leukemia-free and overall survivals, compared with CK/MK AML without the typical features. Blood or bone marrow samples from typical CK/MK AML patients showed defective p53 signaling upon induction by etoposide. In vitro drug sensitivity analysis showed that they were sensitive to APR-246 that targeted mutant p53, but resistant to MDM2 antagonist MI-77301. Novel therapeutic strategies targeting TP53 mutations in CK/MK AML should be developed and tested in clinical trials.
引用
- Leung GMK, Zhang C, Ng NKL, et al. Distinct mutation spectrum, clinical outcome and therapeutic responses of typical complex/monosomy karyotype acute myeloid leukemia carrying TP53 mutations. Am J Hematol. 2019. PMID: 30900772. doi:10.1002/ajh.25469
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。